Zimmer Biomet Holdings, Inc. Class Action Lawsuit - ZBH

The filed complaint alleges that Zimmer Biomet Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: Zimmer Biomet issued a press release on November 5, 2025, announcing its financial results for the third quarter of 2025 and held an earnings call to discuss the same. Among other items, Zimmer Biomet reported net sales of $2 billion, missing consensus estimates of $2.01 billion. Zimmer Biomet also lowered the top end of its outlook for full-year organic revenue growth, projecting gains of 3.5% to 4%, compared to a previous range of 3.5% to 4.5%. Zimmer Biomet reported weakness in international markets and non-core businesses, while its Chief Executive Officer said that distributor challenged and a cancelation of orders in the Middle East and Eastern Europe also weighed on the Company's results. Analysts also noted lower-than-expected growth in U.S. knee and hip replacement sales, expressing concerns about Zimmer Biomet's operational controls. Following this news, Zimmer Biomet's stock price fell over 15% on November 5, 2025.

In order to be eligible to join the ZBH class action lawsuit, you must have incurred a loss on shares of Zimmer Biomet Holdings, Inc. purchased during the class period listed above.